In 2010, Investor was instrumental in the creation of Sobi as the lead shareholder of its predecessors
"During Investor's ownership, Sobi has successfully built a leading hemophilia franchise greatly benefitting patients. In addition, the company has with our support broadened its product portfolio within Hematology and Immunology, organically and through major acquisitions. This has created significant value for Sobi's and Investor's shareholders. Sobi's Board of Directors has recommended Sobi's shareholders to accept the offer. We believe that the offer is financially attractive.
Assuming completion of the offer, Investor's financial position will be further strengthened. We intend to utilize this strength by continuing to invest in existing and new platform companies within
Investor's undertaking to accept the offer will lapse under certain circumstances, including if a third party makes a competing offer for Sobi at a price per share of
Assuming that the offer is declared unconditional, the transaction is expected to be completed in the fourth quarter 2021. Completion of the offer is conditional upon, among other things, the receipt by Agnafit Bidco of all necessary regulatory approvals and that the offer is accepted to such an extent that Agnafit Bidco becomes the owner of more than 90 percent of the shares in Sobi.
[1]
For further information:
Phone +46 70 550 3500
viveka.hirdman-ryrberg@investorab.com
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
magnus.dalhammar@investorab.com
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB,
https://news.cision.com/investor/r/investor-supports-agnafit-bidco-s-bid-for-sobi,c3408587
https://mb.cision.com/Main/1084/3408587/1463304.pdf
(c) 2021 Cision. All rights reserved., source